Nucleus Near-Infrared (nNIR) Irradiation of Single A549 Cells Induces DNA Damage and Activates EGFR Leading to Mitochondrial Fission

Nucleus Near-Infrared (nNIR) Irradiation of Single A549 Cells Induces DNA Damage and Activates EGFR Leading to Mitochondrial Fission

There has been great interest in identifying the biological substrate for light-cell interaction and their relations to cancer treatment. In this study, a near-infrared (NIR) laser is focused into the nucleus (nNIR) or cytoplasm (cNIR) of a single living cell by a high numerical aperture condenser t...

Full description

Bibliographic Details
Main Authors:	Momoh Gbetuwa, Long-Sheng Lu, Tsung-Jen Wang, Yin-Ju Chen, Jeng-Fong Chiou, Tai-Yuan Su, Tzu-Sen Yang
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Series:	Cells
Subjects:	near infrared (NIR) epidermal growth factor receptor (EGFR) mitochondrial fragmentation count (MFC) mitochondrial dynamic cetuximab caffeine
Online Access:	https://www.mdpi.com/2073-4409/11/4/624

Similar Items

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.
by: Alessandro eOttaiano, et al.
Published: (2013-01-01)

Targeting EGFR and Monitoring Tumorigenesis of Human Lung Cancer Cells In Vitro and In Vivo Using Nanodiamond-Conjugated Specific EGFR Antibody
by: Yu-Wei Lin, et al.
Published: (2022-12-01)

EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges
by: Balakarthikeyan Janani, et al.
Published: (2022-03-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
by: Lu Yang, et al.
Published: (2022-06-01)

Prediction of Caffeine and Protein of Arabica Coffee Beans Using Near Infrared Spectroscopy (NIRS)
by: Fitri Yuwita, et al.
Published: (2023-12-01)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01)

Cetuximab Combined With Sonodynamic Therapy Achieves Dual-Modal Image Monitoring for the Treatment of EGFR-Sensitive Non-Small-Cell Lung Cancer
by: Guanhua Qiu, et al.
Published: (2022-02-01)

Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients
by: Gerber Peter, et al.
Published: (2012-02-01)

An Improvement of Exertional Dyspnea by the Reintroduction of Anti-EGFR Antibody in Patients with Metastatic Rectal Cancer Who Developed Cancerous Lymphangiopathy: A Case Report
by: Masatsune Shibutani, et al.
Published: (2024-03-01)

rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects
by: Ji Min Kim, et al.
Published: (2020-10-01)

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
by: Amanda C. Sharko, et al.
Published: (2021-01-01)

Mitochondrial Fission and Fusion: Molecular Mechanisms, Biological Functions, and Related Disorders
by: Mode Al Ojaimi, et al.
Published: (2022-09-01)

A view on EGFR-targeted therapies from the oncogene-addiction perspective
by: Rolando ePerez, et al.
Published: (2013-04-01)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
by: Meiqin Yuan, et al.
Published: (2022-03-01)

Cigarette Smoke Containing Acrolein Upregulates EGFR Signaling Contributing to Oral Tumorigenesis In Vitro and In Vivo
by: Han-Hsing Tsou, et al.
Published: (2021-07-01)

N6-Isopentenyladenosine Impairs Mitochondrial Metabolism through Inhibition of EGFR Translocation on Mitochondria in Glioblastoma Cells
by: Cristina Pagano, et al.
Published: (2022-12-01)

Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation
by: Masami Nozaki, et al.
Published: (2019-10-01)

Epidermal growth factor receptor (EGFR) mutation status and Rad51 determine the response of glioblastoma (GBM) to multimodality therapy with cetuximab, temozolomide and radiation
by: Phyllis Rachelle Wachsberger, et al.
Published: (2013-02-01)

Distinct roles of UVRAG and EGFR signaling in skeletal muscle homeostasis
by: Min Jeong Kim, et al.
Published: (2021-05-01)

Gold nanoparticles affect the antioxidant status in selected normal human cells
by: Daems N, et al.
Published: (2019-07-01)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
by: Adithya Chennamadhavuni, et al.
Published: (2022-06-01)

Photosensitive EGFR-Targeted Nanocarriers for Combined Photodynamic and Local Chemotherapy
by: Elena de las Heras, et al.
Published: (2022-02-01)

PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal CancerSummary
by: Maochao Luo, et al.
Published: (2022-01-01)

Targeting EGFR in Esophagogastric Cancer
by: Steven B. Maron, et al.
Published: (2020-12-01)

Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II
by: Keqiang Zhang, et al.
Published: (2020-09-01)

Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis
by: Qian Wu, et al.
Published: (2022-08-01)

Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways
by: Dmitri Kamashev, et al.
Published: (2023-08-01)

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
by: Stefano Mariani, et al.
Published: (2022-04-01)

RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab
by: Da-Mi Kim, et al.
Published: (2023-07-01)

EGFR targeting of [177Lu] gold nanoparticles to colorectal and breast tumour cells: Affinity, duration of binding and growth inhibition of Cetuximab-resistant cells
by: Rekaya Shabbir, et al.
Published: (2021-10-01)

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
by: Hannah Zaryouh, et al.
Published: (2022-12-01)

The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials
by: Yang Wang, et al.
Published: (2023-10-01)

Recent Advances in Mitochondrial Fission/Fusion-Targeted Therapy in Doxorubicin-Induced Cardiotoxicity
by: Chayodom Maneechote, et al.
Published: (2023-04-01)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
by: Florian Huemer, et al.
Published: (2018-01-01)

Characterisation of cold-induced mitochondrial fission in porcine aortic endothelial cells
by: Leonard Quiring, et al.
Published: (2022-01-01)

Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy
by: A. A. Lyanova, et al.
Published: (2020-07-01)

The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
by: Paweł Michał Potocki, et al.
Published: (2023-09-01)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
by: Cavazzoni Andrea, et al.
Published: (2012-12-01)

Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis
by: Simone Keller, et al.
Published: (2017-12-01)

Transgenic goats producing an improved version of cetuximab in milk
by: Götz Laible, et al.
Published: (2020-11-01)